IIT研究显示,BRL03注射液在实体瘤治疗中具有良好的安全性和初步疗效。 研究药物:BRL03注射液(I期) 登记号:CTR20240722 试验类型:单臂试验 适应症:EBV阳性晚期实体瘤(二线及以上) 申办方:广州百吉生物制药有限公司 用药周期 BRL03注射液的规格:70ml/袋;用法用量:3.0×10^6~3.0×10^7 个TCR-T细胞/公斤;用药时...
TCR-T疗法是一种非常有前途的癌症免疫治疗方法。其需要从患者身上获取T细胞,为T细胞配备新的T细胞受体,使其能够靶向特定的癌症抗原的疗法,这种新型的疗法可以允许医生为每个患者的肿瘤和不同类型的T细胞选择最合适的靶点进行工程改造,使治疗个体化,并为患者提供更大的缓解希望。
简要入排二线后鼻咽癌,EBER(+)半年内接受过嵌合抗原受体修饰的 T 细胞(包括 CAR-T、TCR-T)治疗完整入选标准1) 自愿签署书面知情同意书; 2) 年龄≥18 岁,≤70 岁,男女均可; 3) 预计生存期≥3 个月; 4) 东部肿瘤协作组织(ECOG)体能状况评分为 0-2; 5) 经原位杂交技术检测 EBERs(EBER-FISH)诊断为 ...
Methods: Patients with advanced NPCs were consented and screened for EBV serotype and HLA haplotype. EBV+/HLA-A*02+ patients were enrolled in a rapid titration setting to escalate the single infusion dose from 5x106 to 1.0x107 and 5.0x107 /kg TCR-T cells. After safety evaluation, the ...
9)受试者在接受细胞治疗前 4 周内接受最后一次放疗或抗肿瘤治疗(化疗、靶向治疗或免疫治疗) 10) 受试者目前患有或曾患有其他 3 年内无法治愈的恶性肿瘤,但原位宫颈癌或皮肤基底细胞癌、其他无病生存期超过 5 年的恶性肿瘤除外;11)半年内接受过嵌合抗原受体修饰的T细胞(包括 CAR-T、TCR-T)治疗; 12)合并移...
Adoptive T cell therapy can be effective for Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease and melanoma. Transducing high-affinity TCR genes into T lymphocytes is an emerging method to improve potency and specificity of tumor-specific T cells. However, both methods ne...
Enhancing the expression and function of an EBV-TCR on engineeredT cells by combining Sc-TCR design with CRISPR editingto prevent mispairingCancer immunotherapyImmunizationdoi:10.1038/s41423-020-0396-9Shao-An XueYuan ChenRalf-Holger VossVirad Kisan...
TCR clonotype diversity is an age-associated marker for EBV-associated lymphoproliferative diseases or NK/T cell lymphomadoi:10.1016/j.asjsur.2024.06.026Ting SunDepartment of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;...
The present disclosure provides compositions comprising anti-LMP2 TCR-T cell populations for the treatment of EBV-associated cancers and methods of making and using same.WANG, XIAO-FANALEXANDER, PETERLI, QI-JINGWANG, GUOPING
Savoldo B, Rooney CM, Heslop HE, et al. Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes (CTL) expressing an anti-CD30 chimeric T cell receptor (cTcR) for the treatment of Hodgkin's disease (HD). Mol Ther. 2005; 11:S310....